TBD Meeting (3238-17)

Current treatment with available light-based devices, notably ablative fractional resurfacing, can greatly improve quality of life for patients struggling with scars, according to Kristen Kelly, MD, of the University of California, Irvine.

Using multiple devices, and combining devices with other therapies, are among the strategies that can improve pain and function in these patients, she said in a presentation at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

dermnews@frontlinemedcom.com

Current treatment with available light-based devices, notably ablative fractional resurfacing, can greatly improve quality of life for patients struggling with scars, according to Kristen Kelly, MD, of the University of California, Irvine.

Using multiple devices, and combining devices with other therapies, are among the strategies that can improve pain and function in these patients, she said in a presentation at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

dermnews@frontlinemedcom.com

Current treatment with available light-based devices, notably ablative fractional resurfacing, can greatly improve quality of life for patients struggling with scars, according to Kristen Kelly, MD, of the University of California, Irvine.

Using multiple devices, and combining devices with other therapies, are among the strategies that can improve pain and function in these patients, she said in a presentation at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

dermnews@frontlinemedcom.com

LAS VEGAS – There are now vaccines for two infectious diseases that “are not purely dermatologic, but have a great impact on many patients around the world,” Kenneth J. Tomecki, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

The recent development of a vaccine to protect against malaria, with an efficacy around 40%, “is something we should all be proud of,” said Dr. Tomecki of the Cleveland Clinic. Another advance is that there is now also a vaccine for Ebola that is so effective, it is being stockpiled in African countries in preparation for future Ebola outbreaks, he added.

Dr. Tomecki had no financial conflicts to disclose.

SDEF and this news organization are owned by the same parent company.

dermnews@frontlinemedcom.com

LAS VEGAS – There are now vaccines for two infectious diseases that “are not purely dermatologic, but have a great impact on many patients around the world,” Kenneth J. Tomecki, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

The recent development of a vaccine to protect against malaria, with an efficacy around 40%, “is something we should all be proud of,” said Dr. Tomecki of the Cleveland Clinic. Another advance is that there is now also a vaccine for Ebola that is so effective, it is being stockpiled in African countries in preparation for future Ebola outbreaks, he added.

Dr. Tomecki had no financial conflicts to disclose.

SDEF and this news organization are owned by the same parent company.

dermnews@frontlinemedcom.com

LAS VEGAS – There are now vaccines for two infectious diseases that “are not purely dermatologic, but have a great impact on many patients around the world,” Kenneth J. Tomecki, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

The recent development of a vaccine to protect against malaria, with an efficacy around 40%, “is something we should all be proud of,” said Dr. Tomecki of the Cleveland Clinic. Another advance is that there is now also a vaccine for Ebola that is so effective, it is being stockpiled in African countries in preparation for future Ebola outbreaks, he added.

Dr. Tomecki had no financial conflicts to disclose.

SDEF and this news organization are owned by the same parent company.

dermnews@frontlinemedcom.com

LAS VEGAS – Currently, there are available treatments that are effective in contouring the body, Christopher B. Zachary, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

Some devices can help patients looking for reductions of trouble spots, such as around the abdomen, and are safe and effective, said Dr. Zachary of the University of California, Irvine. However, they are not a realistic option for obese or overweight patients, he added.

In addition, other treatments can be combined with body sculpting devices to optimize results, particularly when removing fat in the submental area, he noted.

Dr. Zachary disclosed relationships with Solta, Zeltiq, Sciton, DUSA, Zimmer, Cutera, Alma, and Amway.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – Currently, there are available treatments that are effective in contouring the body, Christopher B. Zachary, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

Some devices can help patients looking for reductions of trouble spots, such as around the abdomen, and are safe and effective, said Dr. Zachary of the University of California, Irvine. However, they are not a realistic option for obese or overweight patients, he added.

In addition, other treatments can be combined with body sculpting devices to optimize results, particularly when removing fat in the submental area, he noted.

Dr. Zachary disclosed relationships with Solta, Zeltiq, Sciton, DUSA, Zimmer, Cutera, Alma, and Amway.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – Currently, there are available treatments that are effective in contouring the body, Christopher B. Zachary, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

Some devices can help patients looking for reductions of trouble spots, such as around the abdomen, and are safe and effective, said Dr. Zachary of the University of California, Irvine. However, they are not a realistic option for obese or overweight patients, he added.

In addition, other treatments can be combined with body sculpting devices to optimize results, particularly when removing fat in the submental area, he noted.

Dr. Zachary disclosed relationships with Solta, Zeltiq, Sciton, DUSA, Zimmer, Cutera, Alma, and Amway.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – For those starting to use toxins and fillers, “my first advice is to get a good education,” Christopher B. Zachary, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

“Know … how to evaluate your patient, know where the problems are, know what the danger zones are, understand your anatomy,” advised Dr. Zachary of the University of California, Irvine.

“In general, the upper face is an easier place to start,” when learning to work with toxins , he noted. Procedures on the upper face, such as the treatment for crow’s feet or a brow lift, can be “a home run,” while the lower face is much more complicated, he said in the video interview.

Dr. Zachary disclosed relationships with companies including Solta, Zeltiq, Sciton, DUSA, Zimmer, Cutera, Alma, and Amway.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – For those starting to use toxins and fillers, “my first advice is to get a good education,” Christopher B. Zachary, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

“Know … how to evaluate your patient, know where the problems are, know what the danger zones are, understand your anatomy,” advised Dr. Zachary of the University of California, Irvine.

“In general, the upper face is an easier place to start,” when learning to work with toxins , he noted. Procedures on the upper face, such as the treatment for crow’s feet or a brow lift, can be “a home run,” while the lower face is much more complicated, he said in the video interview.

Dr. Zachary disclosed relationships with companies including Solta, Zeltiq, Sciton, DUSA, Zimmer, Cutera, Alma, and Amway.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – For those starting to use toxins and fillers, “my first advice is to get a good education,” Christopher B. Zachary, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

“Know … how to evaluate your patient, know where the problems are, know what the danger zones are, understand your anatomy,” advised Dr. Zachary of the University of California, Irvine.

“In general, the upper face is an easier place to start,” when learning to work with toxins , he noted. Procedures on the upper face, such as the treatment for crow’s feet or a brow lift, can be “a home run,” while the lower face is much more complicated, he said in the video interview.

Dr. Zachary disclosed relationships with companies including Solta, Zeltiq, Sciton, DUSA, Zimmer, Cutera, Alma, and Amway.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – Clinicians can offer patients with scarring the potential for more comprehensive improvement thanks to progress in light-based devices and technologies, Kristen M. Kelly, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

“Not only can we improve these scars from a cosmetic appearance ... but we can also greatly improve the symptoms that patients have,” such as scar-related stinging, discomfort, and movement restrictions or contractures, said Dr. Kelly of the University of California, Irvine.

In addition, combining light-based therapies with medications applied after the treatments can optimize results, she said.

Dr. Kelly disclosed relationships with multiple companies including Allergan, MundiPharma, Syneron-Candela, Light Sciences Oncology, Novartis, Sciton, and ThermiRF.

SDEF and this news organization are owned by the same parent company.

dermnews@frontlinemedcom.com

LAS VEGAS – Clinicians can offer patients with scarring the potential for more comprehensive improvement thanks to progress in light-based devices and technologies, Kristen M. Kelly, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

“Not only can we improve these scars from a cosmetic appearance ... but we can also greatly improve the symptoms that patients have,” such as scar-related stinging, discomfort, and movement restrictions or contractures, said Dr. Kelly of the University of California, Irvine.

In addition, combining light-based therapies with medications applied after the treatments can optimize results, she said.

Dr. Kelly disclosed relationships with multiple companies including Allergan, MundiPharma, Syneron-Candela, Light Sciences Oncology, Novartis, Sciton, and ThermiRF.

SDEF and this news organization are owned by the same parent company.

dermnews@frontlinemedcom.com

LAS VEGAS – Clinicians can offer patients with scarring the potential for more comprehensive improvement thanks to progress in light-based devices and technologies, Kristen M. Kelly, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

“Not only can we improve these scars from a cosmetic appearance ... but we can also greatly improve the symptoms that patients have,” such as scar-related stinging, discomfort, and movement restrictions or contractures, said Dr. Kelly of the University of California, Irvine.

In addition, combining light-based therapies with medications applied after the treatments can optimize results, she said.

Dr. Kelly disclosed relationships with multiple companies including Allergan, MundiPharma, Syneron-Candela, Light Sciences Oncology, Novartis, Sciton, and ThermiRF.

SDEF and this news organization are owned by the same parent company.

dermnews@frontlinemedcom.com

LAS VEGAS – When treating patients with psoriasis, “it is very important for us to treat the entire patient,” and consider the comorbidities, including depression, associated with psoriasis, Jeffrey M. Sobell, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

Depression can be a particular concern for younger patients with more severe psoriasis, said Dr. Sobell of Tufts University, Boston.

When he sees patients aged 18-35 years with significant psoriasis in his practice, he has made it a habit to ask them about depression “and if they’ve ever had thoughts of hurting themselves,” and arranges for mental health follow-up visits for patients about whom he is concerned. “It’s something that’s hard to talk about, but so important,” he said.

Dr. Sobell disclosed relationships with multiple companies including AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis, Regeneron, Sanofi, and Sun Pharma.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – When treating patients with psoriasis, “it is very important for us to treat the entire patient,” and consider the comorbidities, including depression, associated with psoriasis, Jeffrey M. Sobell, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

Depression can be a particular concern for younger patients with more severe psoriasis, said Dr. Sobell of Tufts University, Boston.

When he sees patients aged 18-35 years with significant psoriasis in his practice, he has made it a habit to ask them about depression “and if they’ve ever had thoughts of hurting themselves,” and arranges for mental health follow-up visits for patients about whom he is concerned. “It’s something that’s hard to talk about, but so important,” he said.

Dr. Sobell disclosed relationships with multiple companies including AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis, Regeneron, Sanofi, and Sun Pharma.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – When treating patients with psoriasis, “it is very important for us to treat the entire patient,” and consider the comorbidities, including depression, associated with psoriasis, Jeffrey M. Sobell, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

Depression can be a particular concern for younger patients with more severe psoriasis, said Dr. Sobell of Tufts University, Boston.

When he sees patients aged 18-35 years with significant psoriasis in his practice, he has made it a habit to ask them about depression “and if they’ve ever had thoughts of hurting themselves,” and arranges for mental health follow-up visits for patients about whom he is concerned. “It’s something that’s hard to talk about, but so important,” he said.

Dr. Sobell disclosed relationships with multiple companies including AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis, Regeneron, Sanofi, and Sun Pharma.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – Clinicians should not shy away from light-based treatment of vascular lesions in children, for reasons that include achieving better results when treated early, according to Kristen M. Kelly, MD.

Special considerations include addressing children’s fears. “One of the strategies we use is we have child life specialists who help us” create a friendly and welcoming environment, Dr. Kelly said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar. Consequently, “many of our children actually come in, they’re excited about their visit ... and are looking forward to seeing us at the next visit,” she noted.

Which type of anesthesia to use is another important consideration when treating children, said Dr. Kelly of the University of California, Irvine, in Orange. “For a larger procedure ... one definitely could consider general anesthesia,” but there are risks and benefits to general anesthesia in very young children, and options should be discussed with patients and their families, she said.

Dr. Kelly disclosed relationships with multiple companies including Allergan, MundiPharma, Syneron-Candela, Light Sciences Oncology, Novartis, Sciton, and ThermiRF.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – Clinicians should not shy away from light-based treatment of vascular lesions in children, for reasons that include achieving better results when treated early, according to Kristen M. Kelly, MD.

Special considerations include addressing children’s fears. “One of the strategies we use is we have child life specialists who help us” create a friendly and welcoming environment, Dr. Kelly said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar. Consequently, “many of our children actually come in, they’re excited about their visit ... and are looking forward to seeing us at the next visit,” she noted.

Which type of anesthesia to use is another important consideration when treating children, said Dr. Kelly of the University of California, Irvine, in Orange. “For a larger procedure ... one definitely could consider general anesthesia,” but there are risks and benefits to general anesthesia in very young children, and options should be discussed with patients and their families, she said.

Dr. Kelly disclosed relationships with multiple companies including Allergan, MundiPharma, Syneron-Candela, Light Sciences Oncology, Novartis, Sciton, and ThermiRF.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – Clinicians should not shy away from light-based treatment of vascular lesions in children, for reasons that include achieving better results when treated early, according to Kristen M. Kelly, MD.

Special considerations include addressing children’s fears. “One of the strategies we use is we have child life specialists who help us” create a friendly and welcoming environment, Dr. Kelly said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar. Consequently, “many of our children actually come in, they’re excited about their visit ... and are looking forward to seeing us at the next visit,” she noted.

Which type of anesthesia to use is another important consideration when treating children, said Dr. Kelly of the University of California, Irvine, in Orange. “For a larger procedure ... one definitely could consider general anesthesia,” but there are risks and benefits to general anesthesia in very young children, and options should be discussed with patients and their families, she said.

Dr. Kelly disclosed relationships with multiple companies including Allergan, MundiPharma, Syneron-Candela, Light Sciences Oncology, Novartis, Sciton, and ThermiRF.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – For challenging cases of oral or cutaneous lichen planus, bullous pemphigoid, or lupus, Miriam S. Bettencourt, MD, recommends thinking outside the box and considering off-label treatments.

At the Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar, Dr. Bettencourt discussed such cases, including a series of patients with oral lichen planus who improved with apremilast, an oral phosphodiesterase 4 inhibitor approved for psoriasis.

In a video interview at the meeting, she described one of those patients, a 73-year-old woman with mouth ulcers who was diagnosed with oral lichen planus. Multiple topical and oral therapies proved unsuccessful, and her condition was eventually controlled with apremilast, and the patient is doing well, “with occasional flares,” said Dr. Bettencourt, of the University of Nevada, Las Vegas.

She described this case in her annual presentation at the meeting, titled “Great Cases From the Las Vegas Dermatology Society.”

Dr. Bettencourt disclosed relationships with multiple companies including AbbVie, Aclaris, Celgene, IntraDerm, Pfizer, Promium, Sun Pharma, and Valeant.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – For challenging cases of oral or cutaneous lichen planus, bullous pemphigoid, or lupus, Miriam S. Bettencourt, MD, recommends thinking outside the box and considering off-label treatments.

At the Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar, Dr. Bettencourt discussed such cases, including a series of patients with oral lichen planus who improved with apremilast, an oral phosphodiesterase 4 inhibitor approved for psoriasis.

In a video interview at the meeting, she described one of those patients, a 73-year-old woman with mouth ulcers who was diagnosed with oral lichen planus. Multiple topical and oral therapies proved unsuccessful, and her condition was eventually controlled with apremilast, and the patient is doing well, “with occasional flares,” said Dr. Bettencourt, of the University of Nevada, Las Vegas.

She described this case in her annual presentation at the meeting, titled “Great Cases From the Las Vegas Dermatology Society.”

Dr. Bettencourt disclosed relationships with multiple companies including AbbVie, Aclaris, Celgene, IntraDerm, Pfizer, Promium, Sun Pharma, and Valeant.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – For challenging cases of oral or cutaneous lichen planus, bullous pemphigoid, or lupus, Miriam S. Bettencourt, MD, recommends thinking outside the box and considering off-label treatments.

At the Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar, Dr. Bettencourt discussed such cases, including a series of patients with oral lichen planus who improved with apremilast, an oral phosphodiesterase 4 inhibitor approved for psoriasis.

In a video interview at the meeting, she described one of those patients, a 73-year-old woman with mouth ulcers who was diagnosed with oral lichen planus. Multiple topical and oral therapies proved unsuccessful, and her condition was eventually controlled with apremilast, and the patient is doing well, “with occasional flares,” said Dr. Bettencourt, of the University of Nevada, Las Vegas.

She described this case in her annual presentation at the meeting, titled “Great Cases From the Las Vegas Dermatology Society.”

Dr. Bettencourt disclosed relationships with multiple companies including AbbVie, Aclaris, Celgene, IntraDerm, Pfizer, Promium, Sun Pharma, and Valeant.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – One of the benefits of the recently approved inactivated herpes zoster is its efficacy in older adults, Kenneth J. Tomecki, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

In addition, the vaccine will be recommended not only for healthy adults, but for ill adults aged 50 years and older, said Dr. Tomecki of the department of dermatology at the Cleveland Clinic. “Efficacy is greater than 90% for zoster and postherpetic neuralgia” with the new vaccine, he added.

Vaccination rates among eligible adults with the current vaccine, which is highly effective, are low, but ideally, the advent of the new vaccine will boost vaccination rates, especially in older adults, he noted.

The new vaccine, which will be marketed as Shingrix, was approved in October by the Food and Drug Administration for preventing herpes zoster in adults aged 50 years and older. The currently available herpes zoster vaccine, Zostavax, a live attenuated virus vaccine, was approved by the FDA in 2006.

Dr. Tomecki had no financial conflicts to disclose.

SDEF and this news organization are owned by the same parent company.
 

LAS VEGAS – One of the benefits of the recently approved inactivated herpes zoster is its efficacy in older adults, Kenneth J. Tomecki, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

In addition, the vaccine will be recommended not only for healthy adults, but for ill adults aged 50 years and older, said Dr. Tomecki of the department of dermatology at the Cleveland Clinic. “Efficacy is greater than 90% for zoster and postherpetic neuralgia” with the new vaccine, he added.

Vaccination rates among eligible adults with the current vaccine, which is highly effective, are low, but ideally, the advent of the new vaccine will boost vaccination rates, especially in older adults, he noted.

The new vaccine, which will be marketed as Shingrix, was approved in October by the Food and Drug Administration for preventing herpes zoster in adults aged 50 years and older. The currently available herpes zoster vaccine, Zostavax, a live attenuated virus vaccine, was approved by the FDA in 2006.

Dr. Tomecki had no financial conflicts to disclose.

SDEF and this news organization are owned by the same parent company.
 

LAS VEGAS – One of the benefits of the recently approved inactivated herpes zoster is its efficacy in older adults, Kenneth J. Tomecki, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

In addition, the vaccine will be recommended not only for healthy adults, but for ill adults aged 50 years and older, said Dr. Tomecki of the department of dermatology at the Cleveland Clinic. “Efficacy is greater than 90% for zoster and postherpetic neuralgia” with the new vaccine, he added.

Vaccination rates among eligible adults with the current vaccine, which is highly effective, are low, but ideally, the advent of the new vaccine will boost vaccination rates, especially in older adults, he noted.

The new vaccine, which will be marketed as Shingrix, was approved in October by the Food and Drug Administration for preventing herpes zoster in adults aged 50 years and older. The currently available herpes zoster vaccine, Zostavax, a live attenuated virus vaccine, was approved by the FDA in 2006.

Dr. Tomecki had no financial conflicts to disclose.

SDEF and this news organization are owned by the same parent company.
 

LAS VEGAS – Patients with acne don’t want to be better, they want to be clear, Julie Harper, MD, said at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

Even one lesion on the face can ruin someone’s day, said Dr. Harper, a dermatologist in private practice in Birmingham, Ala., and an author of the 2016 American Academy of Dermatology’s acne management treatment guidelines. Clinicians need to think outside the box and consider a combination of treatments, and they should not underestimate the potential role of oral contraceptives as part of an acne treatment plan, she added.

“As a specialty, we need to learn how to really clear acne,” she said in a video interview. “People don’t want to be 50% better, they want to be clear.”

Dr. Harper disclosed relationships with multiple companies including Allergan, Bayer, Galderma, La Roche-Posay, Promius, and Valeant.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – Patients with acne don’t want to be better, they want to be clear, Julie Harper, MD, said at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

Even one lesion on the face can ruin someone’s day, said Dr. Harper, a dermatologist in private practice in Birmingham, Ala., and an author of the 2016 American Academy of Dermatology’s acne management treatment guidelines. Clinicians need to think outside the box and consider a combination of treatments, and they should not underestimate the potential role of oral contraceptives as part of an acne treatment plan, she added.

“As a specialty, we need to learn how to really clear acne,” she said in a video interview. “People don’t want to be 50% better, they want to be clear.”

Dr. Harper disclosed relationships with multiple companies including Allergan, Bayer, Galderma, La Roche-Posay, Promius, and Valeant.

SDEF and this news organization are owned by the same parent company.

LAS VEGAS – Patients with acne don’t want to be better, they want to be clear, Julie Harper, MD, said at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

Even one lesion on the face can ruin someone’s day, said Dr. Harper, a dermatologist in private practice in Birmingham, Ala., and an author of the 2016 American Academy of Dermatology’s acne management treatment guidelines. Clinicians need to think outside the box and consider a combination of treatments, and they should not underestimate the potential role of oral contraceptives as part of an acne treatment plan, she added.

“As a specialty, we need to learn how to really clear acne,” she said in a video interview. “People don’t want to be 50% better, they want to be clear.”

Dr. Harper disclosed relationships with multiple companies including Allergan, Bayer, Galderma, La Roche-Posay, Promius, and Valeant.

SDEF and this news organization are owned by the same parent company.